Microbial Collagenase: Clinical Trials

52 trials of Microbial Collagenase, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 completed, 5 active not recruiting, 4 unknown, 2 withdrawn. 17 Phase 2, 15 Phase 3, 13 Phase 4, 5 Phase 1, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 217Completed 15, Unknown 1, Withdrawn 1
Phase 315Completed 15
Phase 413Completed 6, Active not recruiting 5, Unknown 2
Phase 15Completed 5
Not applicable2Recruiting 1, Withdrawn 1

Follow Microbial Collagenase: new trials by email Literature Review of Microbial Collagenase trials Research Report on Microbial Collagenase

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
Collagenase Clostridium Histolyticum, RestoreX, Sildenafil - Peyronie Disease
Phase 4Active not recruitingCharitable Union for the Research and Education of Peyronie's Disease402024-10-112026-08-26
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
Collagenase Clostridium Histolyticum, Storz Duolith LiSWT - Peyronie Disease, Erectile Dysfunction
Not applicableRecruitingMayo Clinic602024-01-192026-10-16
A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
Collagenase Clostridium Histolyticum (CCH), Placebo - Plantar Fasciitis
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company2312024-01-032025-09-30
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
Collagenase Clostridium Histolyticum (CCH) - Peyronie Disease, Sexual Dysfunctions, Psychological
Phase 4Active not recruitingUniversity of Miami122023-10-022026-06-04
Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
Collagenase Clostridium Histolyticum, Duolith SD1 T-TOP - Peyronie Disease, Penile Curvature
Not applicableWithdrawnMayo Clinic2023-03-012023-10-10
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
CCH administration, Control - Crossover to CCH, RestoreX - Peyronie's Disease
Phase 4CompletedCharitable Union for the Research and Education of Peyronie's Disease402021-09-202026-08-26
Effectiveness of Splinting After Collagenase Injection
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex], Xiaflex + Hand-Based Custom Orthosis - Dupuytren Contracture, Dupuytren's Disease
Phase 3CompletedFoundation for Orthopaedic Research and Education802021-07-122025-02-26
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery - Peyronie's Disease
Phase 4Active not recruitingCharitable Union for the Research and Education of Peyronie's Disease402020-12-302026-08-26
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
collagenase clostridium histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company352020-10-012022-09-28
Clostridium Histolyticum Collagenase Injection for Urethral Disease
Clostridium Histolyticum Collagenase, Saline - Urethral Stricture
Phase 2CompletedUniversity of South Florida52020-05-222023-11-03
Xiaflex® Plus Testosterone Treatment Pilot Study Protocol
Xiaflex®, Aveed - Peyronie's Disease (PD)
Phase 4CompletedMen's Health Boston202019-01-142020-12-31
Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
Xiaflex® 0.58 mg - Peyronie's Disease
Phase 4UnknownManhattan Medical Research Practice, PLLC202018-10-042018-12-07
Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
collagenase clostridium histolyticum (CCH) - Edematous Skin
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company642018-09-182023-09-07
Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP
CCH (collagenase clostridium histolyticum) - Edematous Fibrosclerotic Panniculopathy
Phase 1CompletedEndo USA Inc., a Keenova Therapeutics Company122018-09-182020-10-06
Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease
Fasciectomy, Collagenase Clostridium Histolyticum - Dupuytren Disease of Finger
Phase 4Active not recruitingRegion Skane602018-03-202025-04-16
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
Collagenase Clostridium Histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company1582017-11-172020-12-29
Trial Comparing Treatment Strategies in Dupuytren's Contracture
Percutaneous needle fasciotomy (PNF), Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex], Limited fasciectomy (LF) - Dupuytren Contracture
Phase 4Active not recruitingTampere University3022017-09-152026-04-29
Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's
collagenase injection, limited palmar fasciectomy - Dupuytren's Disease
Phase 3CompletedMcMaster University222017-07-082023-07-18
Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)
Saline, EN3835 - Fibroids, Uterine, Leiomyoma
Phase 1CompletedAdvance Biofactures Corporation152016-10-272019-07-10
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Collagenase Clostridium Histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company2592016-10-052020-11-24

Showing 20 of 52. Sign in to see all of them.

Conditions studied

Dupuytren Contracture (16)  ·  Penile Induration (14)  ·  Cellulite (8)  ·  Bursitis (3)  ·  Contracture (3)  ·  Erectile Dysfunction (2)  ·  Lipoma (2)  ·  Connective Tissue Diseases (1)  ·  Cutis Laxa (1)  ·  Fasciitis, Plantar (1)  ·  Genital Diseases, Male (1)  ·  Hypogonadism (1)  ·  Leiomyoma (1)  ·  Recurrence (1)  ·  Sexual Dysfunctions, Psychological (1)

Sponsors

Endo USA Inc., a Keenova Therapeutics Company (26)  ·  Charitable Union for the Research and Education of Peyronie's Disease (3)  ·  Stony Brook University (3)  ·  Mayo Clinic (2)  ·  Advance Biofactures Corporation (1)  ·  Asahi Kasei Therapeutics Corporation (1)  ·  Foundation for Orthopaedic Research and Education (1)  ·  Gerut, Zachary, M.D. (1)  ·  Hospital for Special Surgery, New York (1)  ·  Indiana Hand to Shoulder Center (1)  ·  Manhattan Medical Research Practice, PLLC (1)  ·  McMaster University (1)  ·  Men's Health Boston (1)  ·  Region Skane (1)  ·  Sheba Medical Center (1)

Countries

United States (41)  ·  Australia (7)  ·  Canada (3)  ·  Sweden (3)  ·  United Kingdom (3)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  New Zealand (1)  ·  Norway (1)  ·  Spain (1)

Top investigators

Veronica Urdaneta, MD (5)  ·  Gregory J. Kaufman, MD (3)  ·  Veronica Urdaneta, MD MPH (3)  ·  Veronica Urdaneta, MD, MPPH (3)  ·  Gregory Kaufman, MD (2)  ·  Landon Trost, MD (2)  ·  Marie A Badalamente, PhD (2)  ·  Abraham Morgentaler, MD (1)  ·  Achilleas Thoma, MD MSc FRCSC (1)  ·  Aleksi RP Reito, M.D., Ph.D., adjunct professor (1)  ·  Antti OV Malmivaara, M.D., Ph.D., adjunct professor (1)  ·  David Hernandez (1)  ·  Edward Wang, MD (1)  ·  George Omburo (1)  ·  Hannu Kautiainen, MSc (1)

Results publications

PMID 19726771, PMID 26199168, PMID 15541123, PMID 17437780, PMID 17617144, PMID 17983892, PMID 21315996, PMID 21967070, PMID 23376148, PMID 24745607, PMID 25388099, PMID 26126692, PMID 26491251, PMID 27313184, PMID 28854973, PMID 28974406, PMID 30808670, PMID 34323413, PMID 38346307, PMID 41334972, PMID 9679876